Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Expert Opinion on Drug Delivery|August 26, 2011
Insulin administration: selecting the appropriate needle and individualizing the injection techniqueBirtha Hansen, Irina Matytsina
Drug and Alcohol Review|November 30, 2006
Mental health and alcohol, drugs and tobacco: a review of the comorbidity between mental disorders and the use of alcohol, tobacco and illicit drugsEva Jané-Llopis, Irina Matytsina
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 9, 2025
Model-informed drug development of Mim8 - a next-generation bispecific antibody for treatment of haemophilia AMads Kreilgaard, Irina Matytsina, Paula Persson
Research and Practice in Thrombosis and Haemostasis|September 25, 2023
Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adultsPaula Persson, Anne-Beth Amstrup, Hans Veit Coester, et al.
Medicine|February 1, 2018
A case report of acute inferior myocardial infarction in a patient with severe hemophilia A after recombinant factor VIII infusionSilva Zupančić-Šalek, Marijo Vodanović, Dražen Pulanić, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 10, 2019
Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trialHassan Yaish, Tadashi Matsushita, Meriem Belhani, et al.
Journal of Thrombosis and Haemostasis : JTH|December 24, 2023
FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimeticSteven R Lentz, Pratima Chowdary, Lidia Gil, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 18, 2021
Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII-treated patients with haemophilia A switching to turoctocog alfa in a noninterventional studyCarmen Escuriola Ettingshausen, Olga Katsarou, Barbara Faganel Kotnik, et al.
Thrombosis and Haemostasis|December 31, 2019
Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients with Severe Haemophilia AAndreas Tiede, Ana Rosa Cid, Georg Goldmann, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 8, 2018
Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trialSteven R Lentz, Dragana Janic, Kaan Kavakli, et al.
Pageof 2